The Coalition for Epidemic Preparedness Innovations (CEPI) announced on June 1, 2026, that it will accelerate the development of three vaccine candidates against Bundibugyo ebolavirus (BDBV), committing over $60 million to address an ongoing outbreak in the Democratic Republic of the Congo. CEPI has allocated up to $50 million to Moderna for the preclinical development and Phase 1 clinical testing of its mRNA-based BDBV vaccine candidate. This funding will also enable Moderna to enhance its manufacturing capabilities and prepare for large-scale Phase 2/3 trials if the vaccine progresses through early testing. Moderna CEO Stéphane Bancel stated that the mRNA platform could significantly contribute to rapid responses to emerging infectious disease threats.
✓ AI-Debiased Article
10
Wire-neutral
provisional
✓ No loaded language, vague sourcing, or framing detected.
CEPI allocates $50 million to Moderna for mRNA Ebola vaccine development
CEPI has pledged over $60 million to expedite the development of vaccines against Bundibugyo ebolavirus, including $50 million to Moderna for its mRNA-based vaccine. This funding aims to support preclinical and Phase 1 testing while enhancing manufacturing capabilities for potential large-scale trials.
Companies
Moderna (MRNA)
People
Stéphane Bancel (CEO)
Annotating as
No note attached
on this article.
Related Tickers
MRNA
Original vs. Neutral
Original Headline
Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo
Neutral Headline
CEPI allocates $50 million to Moderna for mRNA Ebola vaccine development